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Abstract 28 
 29 
Accurate identification of Alzheimer’s disease (AD) is still of major clinical importance 30 
considering the current lack of non-invasive and low-cost diagnostic approaches. Detection of 31 
early-stage AD is particularly desirable as it would allow early intervention and/or recruitment 32 
of patients into clinical trials. There is also an unmet need for discrimination of AD from 33 
dementia with Lewy bodies (DLB), as many cases of the latter are misdiagnosed as AD. 34 
Biomarkers based on a simple blood test would be useful in research and clinical practice. 35 
Raman spectroscopy has been implemented to analyse blood plasma of a cohort that consisted 36 
of early-stage AD, late-stage AD, DLB and healthy controls. Classification algorithms 37 
achieved high accuracy for the different groups: early-stage AD vs healthy with 84% 38 
sensitivity, 86% specificity; late-stage AD vs healthy with 84% sensitivity, 77% specificity; 39 
DLB vs healthy with 83% sensitivity, 87% specificity; early-stage AD vs DLB with 81% 40 
sensitivity, 88% specificity; late-stage AD vs DLB with 90% sensitivity, 93% specificity; and 41 
lastly, early-stage AD vs late-stage AD 66% sensitivity and 83% specificity. G-score values 42 
were also estimated between 74-91%, demonstrating that the overall performance of the 43 
classification model was satisfactory. The wavenumbers responsible for differentiation were 44 
assigned to important biomolecules which can serve as a panel of biomarkers. These results 45 
suggest a cost-effective, blood-based biomarker for neurodegeneration in dementias.  46 
 47 
 48 
 49 
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Introduction 52 
Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) constitute the two 53 
most common causes of dementia. AD and DLB can share common symptoms and clinical 54 
characteristics, which can lead to misdiagnosis. A clear distinction between these two causes 55 
of dementia is necessary in terms of pharmacological treatment and outcome evaluation 1, 2. 56 
The neuropathological hallmarks of AD include senile plaques (containing accumulated 57 
amyloid-beta (Aβ) peptide) and neurofibrillary tangles (composed of hyperphosphorylated tau 58 
protein), while in DLB the hallmark pathology is the abnormal aggregation of α-synuclein into 59 
Lewy bodies and Lewy neurites 3, 4. The ability to index the presence of these pathological 60 
features in very early stages (i.e., prodromal disease), or even before symptoms occur (i.e., pre-61 
clinical disease), would allow an earlier intervention before irreversible neuronal death occurs, 62 
as well as facilitating early recruitment into clinical trials.  63 
Accurate detection of dementia is essential for improving the lives of those affected. 64 
Current diagnostic approaches employ neuroimaging techniques, such as magnetic resonance 65 
imaging (MRI) and positron emission tomography (PET) scans (amyloid-PET and more 66 
recently tau-PET), or cerebrospinal fluid (CSF) biomarkers, but these methods have many 67 
limitations 5-8. A combination of family and clinical history, as well as a series of different 68 
memory and psychological tests is often required for diagnosis, but not all pathologically 69 
similar cases will present with the same “clinical phenotype”; many studies have shown 70 
contradictory results regarding the suitability of these biomarkers for accurate diagnosis. 71 
Recently, blood biomarkers have emerged as a potential means to test for neurodegenerative 72 
diseases, with some being capable of detecting early-stage disease 9-11. The rationale behind 73 
the use of blood samples is based on the daily release of 500 ml CSF into the bloodstream, 74 
which potentially renders blood a rich source of brain biomarkers 12.  75 
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Raman is a spectroscopic technique that extracts biological information by applying a 76 
monochromatic, laser light onto the sample under interrogation; electrons are thus excited to 77 
virtual energy levels. When these electrons return to the original energy level, in the form of a 78 
photon, there is no energy shift (known as elastic or Rayleigh scattering), whereas when they 79 
return to a lower or a higher energy level there is a gain or loss of energy, respectively (known 80 
as inelastic or Raman scattering) 13. The shift in the energy allows the generation of a spectrum 81 
which is indicative of the chemical bonds present in the sample. The characteristic spectra that 82 
are derived from Raman spectroscopy, represent a number of different biomolecules within a 83 
sample (e.g., proteins, carbohydrates, lipids, DNA) 14. Recent studies have employed Raman 84 
spectroscopy to study different diseases, such as malaria, oral and colorectal cancer, in 85 
biological fluids 15-17.  86 
 The aim of the present study was to diagnose patients with Alzheimer’s disease, in early 87 
and late disease stages, and patients with DLB, as well as to discriminate between AD and 88 
DLB. To achieve this, blood plasma was analysed with Raman spectroscopy as a minimally 89 
invasive procedure that would also allow repeated measurements for follow-up of individuals. 90 
Results  91 
We enrolled 56 individuals into this study who were classified into 4 groups; early stage 92 
AD (n=11; age range: 50-74 years), late stage AD (n=15; age range: 50-79 years), DLB (n=15; 93 
age range: 23-73 years) and healthy controls (n=15; age range: 23-73 years) (Table 1). Early 94 
and late-stage AD was defined according to the duration of illness, from designated age at onset 95 
up to age at sample collection. P-values were calculated based on age and statistical differences 96 
were detected only for the following two subgroup comparisons: Late AD vs Healthy (P=0.004) 97 
and DLB vs Healthy (P <0.001). For all the other comparison groups (Early AD vs Healthy, 98 
Early AD vs DLB, Late AD vs DLB, Early AD vs Late AD), there was no statistical difference 99 
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observed due to age (P >0.005) (Supplementary Table 1). Even though there was age difference 100 
between the controls and AD individuals, no correlation was observed between age and AD 101 
spectra after using partial least squares regression (R2 = 0.107, 2 latent variables with 99.93% 102 
cumulative explained variance) and no statistical difference was observed in the spectra of AD 103 
patients with age lower and higher than 54 years of age (average control age) with a 95% 104 
confidence level (P> 0.005). This indicates that age did not affect the spectral distribution 105 
within the AD class. Similarly, no statistical differences were observed in the Raman spectra 106 
of the different groups due to gender (male vs female) (Supplementary Fig. 8). 107 
Early stage AD vs healthy individuals.  After pre-processing of the spectral data, 108 
principal component analysis followed by linear discriminant analysis (PCA-LDA) was 109 
applied to the derived dataset. A one-dimensional (1D) scores plot was generated to account 110 
for differences and similarities between early stage AD and healthy subjects (Fig. 1A); after 111 
statistical analysis, the two classes showed significant differences (P <0.0001, 95% CI = 0.0503 112 
to 0.0622). A loadings plot served as a biomarker extraction method, identifying the top six 113 
peaks responsible for differentiation: 1650 cm-1, 1529 cm-1, 1432 cm-1, 1161 cm-1, 996 cm-1 114 
and 911 cm-1 (Fig. 1B). A statistical test was performed on each peak individually to calculate 115 
the P-value and investigate the differences in Raman intensity between the two groups 116 
(Supplementary Fig. S2, Supplementary Table 2). Figure 1C summarises the tentative 117 
assignments along with the P-values for these peaks (denoted with asterisks). Further analysis 118 
was conducted to classify the two classes; support vector machine (SVM) was the classification 119 
algorithm that was used, achieving 84% sensitivity and 86% specificity, with the G-score 120 
estimated at 85% and Youden’s index at 70% (Table 2, Supplementary Fig. 1A). 121 
Late AD vs healthy individuals.  A similar approach was followed for the discrimination 122 
between late AD and healthy individuals. Figure 2A represents the scores plot after cross 123 
validated PCA-LDA and reveals statistically significant differences between the groups (P 124 
6 
 
<0.0001, 95% CI = 0.0655 to 0.0834). The top six discriminatory peaks that were selected for 125 
this comparison group were 1648 cm-1, 1530 cm-1, 1432 cm-1, 1259 cm-1, 1164 cm-1 and 1003 126 
cm-1 (Fig. 2, Supplementary Fig. S3 and Supplementary Table 2). After the SVM classification, 127 
late AD was discriminated from healthy individuals with 84% sensitivity, 77% specificity and 128 
the G-score estimated at 80% and Youden’s index at 61% (Table 2, Supplementary Fig. 1B). 129 
DLB vs healthy individuals.  Scores plot was again generated after cross validated 130 
PCA-LDA to compare DLB with healthy controls. Statistically significant differences were 131 
found between the groups (P <0.0001, 95% CI = 0.0982 to 0.1166) and the wavenumbers that 132 
were mostly responsible for this discrimination are shown in the respective loadings plot (Fig. 133 
3B): 1647 cm-1, 1604 cm-1, 1418 cm-1, 1384 cm-1, 1002 cm-1 and 933 cm-1. The differences in 134 
Raman intensity for each wavenumber are shown in more detail in Supplementary Fig. 4 and 135 
Supplementary Table 2. Sensitivity and specificity, after SVM, were 83% and 87%, 136 
respectively, while the G-score was calculated at 85% and Youden’s index at 70% (Table 2, 137 
Supplementary Fig. 1C). 138 
Early stage AD vs DLB. The scores plot for the comparison between early stage AD and 139 
DLB is shown in Fig. 4A. After statistical analysis, the difference between these two cohorts 140 
was statistically significant (P <0.0001, 95% CI = -0.0791 to -0.0649). The wavenumbers that 141 
were found as the most important, after cross-validated PCA-LDA are shown along with their 142 
tentative assignments in Fig. 4 and were the following: 1645 cm-1, 1513 cm-1, 1376 cm-1, 1253 143 
cm-1, 1161 cm-1 and 1003 cm-1 (Supplementary Fig. 5 and Supplementary Table 2). The 144 
sensitivity and specificity values from this comparison were 81% and 88%, respectively, with 145 
the G-score at 84% and Youden’s index at 69% (Table 2, Supplementary Fig. 1D).  146 
Late AD vs DLB.  Analyses were conducted to discriminate between late AD and DLB 147 
(Fig. 5). Significant differences were found after statistical analysis on the PCA-LDA scores 148 
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plot (P <0.0001; 95% CI = 0.138 to 0.1596). The following are the top six wavenumbers that 149 
were found to be responsible for the observed differentiation: 1646 cm-1, 1614 cm-1, 1437 cm-150 
1, 1216 cm-1, 1164 cm-1 and 1003 cm-1. Differences in the Raman intensity at these peaks are 151 
given in Supplementary Fig. 6 and Supplementary Table 2. The tentative assignments for these 152 
wavenumbers are shown in Fig. 5C. Sensitivity and specificity were 90% and 93%, 153 
respectively, with G-score being 91% and Youden’s index at 84% (Table 2, Supplementary 154 
Fig. 1E). 155 
Early AD vs late AD. A comparison between early and late-stage AD patients was also 156 
performed. After cross validated PCA-LDA, the scores plot revealed statistically significant 157 
differences between the two groups (P <0.0001; 95% CI = -0.0943 to -0.0624) (Fig. 6). The 158 
loadings plot denoted the following six wavenumbers as the most important: 1650 cm-1, 1476 159 
cm-1, 1432 cm-1, 1161 cm-1, 1003 cm-1, 642 cm-1 (Supplementary Fig. 7 and Supplementary 160 
Table 2). After classification of the two populations, 66% of the early AD spectra were 161 
correctly identified with 34% been misclassified as late AD; and 83% of the late AD cases 162 
were correctly identified with 17% misclassified as early stage AD (Table 2). G-score was 163 
calculated at 74% and Youden’s index at 49% (Table 2, Supplementary Fig. 1F). 164 
Discussion 165 
Amyloid PET imaging has been shown to improve the diagnostic accuracy of AD 18. 166 
However, one of the limitations is that only subjects with advanced dementia and relatively 167 
heavy plaque densities will be amyloid PET-positive; thus, individuals may not be identified 168 
early enough to be used in prevention studies using anti-amyloid therapeutics 19. The detection 169 
accuracy of neuropathologically defined AD with PET imaging has been estimated at 69-95% 170 
sensitivity and 83-89% specificity 20. In the case of DLB patients, PET imaging shows 171 
increased Aβ deposition in >50% of patients with DLB which limits its value in distinguishing 172 
between AD and DLB 3. In a recent study, clinical and pathological diagnoses were compared 173 
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and DLB patients were identified with 73% sensitivity and 93% specificity; such findings 174 
suggest that there is still need for improvement in discriminating between these conditions 21. 175 
When using MRI for AD diagnosis, a decreased volume of hippocampus and other temporal 176 
lobe structures is indicative of neurodegeneration; visual rating scales evaluating the degree of 177 
atrophy provide ~80-85% sensitivity and specificity when comparing AD to healthy 178 
individuals and slightly lower sensitivity and specificity when comparing to amnestic mild 179 
cognitive impairment (MCI) 6. However, atrophy patterns can be similar in different diseases 180 
while at the same time some unusual forms of AD may have atypical patterns 22.  181 
Established CSF biomarkers that are currently used in clinical practise to diagnose AD, 182 
also known as “core biomarkers”, include decreased levels of Aβ42, or decreased Aβ42:Aβ40 183 
ratio, and increased levels of total tau (T-tau) or hyperphosphorylated tau (P-tau) 23. In a 184 
systematic review and meta-analysis, a number of different biomarkers has been associated 185 
with AD in both CSF and blood; namely, neurofilament light chain (NfL), neuron-specific 186 
enolase (NSE), visinin-like protein 1 (VLP-1), heart fatty acid binding protein (HFABP), 187 
chitinase-3-like protein 1 (YKL-40) in CSF, as well as T-tau and P-tau in blood plasma 10, 24, 188 
25. More recently, an elevated level of plasma NfL has been suggested as a promising biomarker 189 
to distinguish AD and MCI from healthy subjects. The accuracy for the comparison between 190 
AD and healthy controls, after testing for NfL, was 87%, which is comparable to accuracies 191 
achieved by CSF testing (88% Aβ42; 90% T-tau; 87% P-tau; 89% NfL) and plasma tau (78%) 192 
11. Another study, discovered and validated a set of ten lipids in plasma to detect preclinical 193 
AD in cognitively normal older adults within a 2-3 year timeframe; this panel achieved 90% 194 
accuracy 9. Even though it is now established that the α-synuclein gene (SNCA) is associated 195 
with a few families with Parkinson’s disease (PD) and DLB, CSF α-synuclein is not yet proven 196 
as a potential biomarker. CSF and blood biomarkers for the diagnosis of DLB remain elusive, 197 
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with Aβ, Τ-tau and P-tau remaining the most current measurements to predict cognitive decline 198 
and determine associated AD pathology 3. 199 
In the present study, we included patients with AD, in both early and later stages of the 200 
disease, DLB, as well as heathy individuals. The blood-based Raman spectroscopic technique, 201 
provided excellent diagnostic accuracy not only between diseased and non-diseased states, but 202 
also between the two different types of dementia. Statistically significant age differences were 203 
only observed for Late AD vs Healthy (P=0.004) and DLB vs Healthy (P <0.001). The age 204 
difference between healthy controls and both Late AD and DLB patients was somehow 205 
expected as these diseases manifest mainly in older individuals. A larger dataset containing a 206 
wider age range would be necessary for adjusting the model for age. However, the fact that 207 
diagnostic accuracies remain exceptionally high for the subgroups with no age differences (e.g., 208 
Late AD vs DLB showing 90% sensitivity and 93% specificity), implies that the age factor was 209 
not solely responsible for the achieved segregation between the cohorts. Similarly, no statistical 210 
differences were observed due to gender after calculating the P values for each spectral 211 
wavenumber; therefore, gender differences did not change the spectral profile. 212 
Raman spectroscopy can reveal invaluable information about a biological sample as it 213 
provides the overall status of a sample, indicating disease. The results from such an approach 214 
are comparable to, and in some cases even better than, conventional methods, as they allow for 215 
simultaneous investigation of a panel of different biomarkers and therefore may be more 216 
suitable for complex diseases. Furthermore, Raman allows for a low-cost, label-free and non-217 
destructive diagnosis in contrast to current imaging techniques and molecular CSF and/or blood 218 
tests. Previous studies have estimated the cost of an MRI and PET scan at £163 and £844, 219 
respectively, while an enzyme-linked immunosorbent assay (ELISA) measurement (96-well 220 
plate) of the core biomarkers (Aβ42, T-tau, P-tau) costs £826 per kit 26, 27. In contrast, a blood 221 
test employing Raman spectroscopy is negligible in terms of consumables although there 222 
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would be costs in terms of employee time for samples preparation and analysis; overall cost 223 
would fall dramatically as the data infrastructure to allow remote classification of samples 224 
became available. Even the upfront cost or Raman instrumentation, often varying from £3,000-225 
£150,000, is low in comparison with other approaches and would again fall with the 226 
development of hand-held devices; also the running costs are minimal with electrical power 227 
being the only requirement. Over the longer-term, lasers may need to be replaced (~every 6-7 228 
years), but daily running costs are close to zero. 229 
Discriminatory peaks have also been identified for all of the different comparison 230 
groups and could possibly be used as biomarkers for differential diagnosis or screening of high-231 
risk populations. For instance, higher levels of Amide II peaks (~1530 cm-1) were seen in both 232 
early (P <0.0001) and late stage AD (P <0.0001) patients and could possibly be represented by 233 
an increase in tau proteins or NfL in plasma, which have been suggested previously as 234 
promising biomarkers (Supplementary Fig. 2, Supplementary Fig. 3) 11. Also, the observed 235 
decrease in lipids (~1432 cm-1) could be due to damaged phospholipid membranes caused by 236 
oxidative stress. These findings are in line with previous results of a larger-scale study our 237 
research team conducted, in which infrared (IR) spectroscopy was employed to diagnose AD 238 
28. An advantage of Raman spectroscopy over IR is its ability to analyse aqueous samples which 239 
would allow the analysis of fresh samples without the need of prior dehydration; this would be 240 
particularly beneficial for use in a clinic.  Noticeably, in this preceding study, lipid peaks were 241 
also decreased (~1740 cm-1, P <0.05; ~1450 cm-1, P <0.005) and Amide II was also increased 242 
(~1540 cm-1, P = 0.003) in AD patients. However, Amide I (~1650 cm-1), which is indicative 243 
of Aβ load, was not found to be statistically different (P = 0.12), in contrast to the current study 244 
where it was significant in both early (P = 0.0003, 95% CI = 0.0008 to 0.0028) and late stage 245 
AD (P <0.0001, 95% CI = 0.0016 to 0.0029). Previous studies have noted altered levels of 246 
aromatic amino acids in plasma and serum of AD patients 29. Some studies have shown an 247 
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increase in phenylalanine in the brain of AD subjects 30-32, while others suggest a decrease 33, 248 
34. In our study, the level of phenylalanine was increased in DLB cases, whereas in late AD 249 
phenylalanine was decreased when compared to healthy subjects. Between AD and DLB 250 
patients, the latter cohort showed higher levels of phenylalanine, which could possibly relate 251 
to their α-synuclein pathology (Supplementary Fig. 5). Previous studies have shown altered 252 
metabolic profiles of PD patients (also related to α-synuclein aggregation) when compared to 253 
normal controls, and these differences were related to metabolic pathway variations such as 254 
phenylalanine metabolism 35-37.  255 
We were particularly interested in examining early stage AD cases as it is of crucial 256 
importance to identify individuals before brain damage becomes very severe. Evidence of 257 
changes here would allow for an on-time intervention, potentially to slow down the disease, 258 
psychologically prepare the affected person and their family, as well as provide them with the 259 
opportunity to take part in early intervention trials. Surprisingly, the diagnostic accuracy was 260 
slightly higher for early AD than for late AD. After comparison of these two groups, 66% of 261 
early AD and 83% of late AD were correctly classified. Of the wavelengths which were shown 262 
to contribute the most to the segregation between the classes, a peak assigned to Amide II 263 
proteins (~1476 cm-1) and a peak assigned to C-C and C-S vibrations of proteins (~642 cm-1) 264 
were found to be statistically significant (Supplementary Fig. 7). A potential explanation for 265 
the decreased level of Amide II in early stage AD cases could be the lower density of 266 
neurofibrillary tangles in the brain during early stages. Previous studies have suggested that 267 
kinase mutations and dysfunction play an important role in the development of disorders such 268 
as cancer and neurodegeneration 38. Specifically, cyclin-dependent kinase 5 (cdk5), which is 269 
involved in the abnormal hyperphosphorylation of tau, has been suggested to accumulate at a 270 
relatively early stage in the neocortex 39; more recent research has also shown that a cellular 271 
stress response, caused by accumulation of misfolded proteins, induces the activity of a major 272 
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tau kinase (GSK-3β) and occurs at an early stage of neurofibrillary degeneration leading to AD 273 
pathogenesis 40. Therefore, this may potentially explain the increased level of the protein peak 274 
at 642 cm-1. Special attention was also given to the accurate diagnosis of DLB and 275 
differentiation from AD which is especially important to provide the appropriate treatment; 276 
DLB cases respond well to cholinesterase inhibitors but have severe neuroleptic sensitivity 277 
reactions, which are associated with significantly increased morbidity and mortality 41.  278 
A critical aspect for every new biomarker, diagnostic or treatment approach is the 279 
repetition and validation of the analytical process and in different cohorts. Previously, a few 280 
studies also employed Raman spectroscopy to diagnose AD in blood, achieving high 281 
classification accuracy. Carmona et al. distinguished AD (n=35) from normal (n=12) with 89% 282 
sensitivity and 92% specificity 42. Ryzhikova et al. included serum samples from 20 AD 283 
patients, 18 patients with other neurodegenerative dementias (OD) (5 with DLB, 10 with 284 
Parkinson’s disease dementia and 3 with frontotemporal dementia) and 10 healthy individuals 285 
and achieved 95% sensitivity and specificity 43. However, the fact that a range of different 286 
dementias were all taken in the same group, may obscure the actual classification capability 287 
between AD and DLB. Moreover, no spectroscopic approach has been employed so far to 288 
investigate DLB in more detail.  289 
A limitation of the current study is the small number of participants, which can affect 290 
sensitivity and specificity estimates. However, G-score values were estimated at 74-91%, 291 
denoting that the models were not overfitted. G-score does not account the size of classes, thus 292 
providing robust information about the classification ability even in smaller cohorts 44. 293 
Youden’s index values ranged between 49% (early AD vs late AD) and 84% (late AD vs DLB). 294 
This parameter is a probability indicator of the model’s ability to avoid failure. Youden’s 295 
indexes above 70% for early AD vs healthy, DLB vs healthy and late AD vs DLB indicate that 296 
these models have low probability of misclassification in the future. Another limitation of this 297 
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study, as well as similar previous ones, is the lack of serial samples from the same individuals 298 
which would validate the results and demonstrate repeatability. 299 
In summary, diagnosis of early stage AD, late stage AD, DLB as well as differentiation 300 
between the two dementias was achieved, opening a new road for potential applications in a 301 
clinical setting. Some of the future uses of spectroscopy could be the detection of 302 
prodromal/pre-demented cases; the differential diagnosis of different dementias that would 303 
allow the appropriate treatment and/or recruitment into clinical trials; and the further 304 
monitoring of patients that do finally take part in clinical trials. 305 
Methods 306 
Patient information.  We enrolled 56 individuals into this study who were classified 307 
into four groups; early stage AD (n=11), late stage AD (n=15), DLB (n=15) and healthy 308 
controls, usually spouses (n=15). Early and late-stage AD was defined according to the duration 309 
of illness, from designated age at onset up to age at sample collection. Early stage was defined 310 
as up to two years from designated age at onset, whereas late stage AD was defined as any 311 
duration beyond this time point. Clinical and demographic data is summarised in Table 1. 312 
Information on apolipoprotein ε4 (APOE4) status and gender was not available for two subjects 313 
from the healthy control group. Patients were recruited at Salford Royal Hospital (Salford, UK) 314 
with informed consent prior to enrolment in accordance with Local Ethical Approval 315 
(05/Q1405/24 conferred by North West 10 Research Ethics Committee Greater Manchester 316 
North). Patients were diagnosed according to battery of psychological testing (Manchester 317 
Neuropsychology Inventory) performed at a Specialist referral Centre (Cerebral Function Unit, 318 
Greater Manchester Neurosciences Centre, Salford Royal Hospital). All methods were 319 
performed in accordance with the relevant guidelines and all other applicable laws and 320 
regulations. At time of diagnosis patients were not receiving any medications, such as 321 
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anticholinesterase treatments. Most patients had received MRI scans but these were used only 322 
to support the neuropsychological outcomes. 323 
Sample preparation and APOE genotyping. Whole blood samples were collected into 324 
EDTA tubes, centrifuged at 2000 rpm at 4oC for 10 min to separate erythrocytes from plasma. 325 
Plasma was collected in 0.5 mL clean, plastic tubes, stored at -80oC and thawed at room 326 
temperature prior to spectroscopic interrogation. After the samples were thawed, 50 μL were 327 
deposited on glass slides covered with aluminium foil, which has been shown to be featureless 328 
in Raman 14, and were then left to air-dry overnight. DNA was extracted by routine methods 329 
from blood samples of patients and control subjects; APOE alleles were determined by PCR 330 
45. 331 
Raman spectroscopy. Raman spectra were collected with an InVia Renishaw Raman 332 
spectrometer coupled with a charge-coupled device (CCD) detector and a Leica microscope. 333 
A 200 mW laser diode was used at a wavelength of 785 nm with a grating of 1200 l/mm, and 334 
the system was calibrated to 520.5 cm-1 with a silicon source, before every run. After trial-and-335 
error measurements to optimise the experimental parameters, we concluded to a 10 second 336 
exposure time, 5% laser power and 2 accumulations at a spectral range 2000-400 cm-1 to 337 
achieve optimum spectral quality. Twenty-five point spectra were taken per sample using a 338 
50× objective to focus the laser beam on the sample.  339 
Pre-processing of spectral data and multivariate analysis. Spectra were initially 340 
corrected for cosmic rays using the Renishaw WiRe software. An in-house developed IRootLab 341 
toolbox (http://trevisanj.github.io/irootlab/) was then implemented within MATLAB 342 
(MathWorks, Natick, USA) for further pre-processing and computational analysis of the data. 343 
All spectra were cut at 1750-500 cm-1, first order differentiated with Savitzky-Golay (SG) 344 
(window of 9 points; 2nd polynomial filter) to smooth out the noise and vector normalised to 345 
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account for non-biological differences, such as varying concentration or thickness of the 346 
sample; the resulting dataset was then mean-centered before implementation of cross-validated 347 
(k-fold=10, leave-one-out) principal component analysis followed by linear discriminant 348 
analysis (PCA-LDA).  The leave-one-out cross-validation was implemented to avoid 349 
overfitting. This ensures that one sample is removed from the training set and predicted as 350 
external sample during model construction in an interactive process until all samples are 351 
predicted; this provides more realistic classification results. All classification models were 352 
validated using 10% of the samples in a test set. PCA is an unsupervised method that reduces 353 
the spectral dataset to only a few important principal components (PCs) which are responsible 354 
for the majority of the variation; using a Pareto function, a number of 10 PCs was found as 355 
optimal. LDA is a supervised technique, often coupled with PCA, to maximise the between-356 
class distance and minimise the within-class distance. Scores plots and loadings plots were 357 
generated after PCA-LDA to visualise the differences and similarities between the groups as 358 
well as to identify specific spectral peaks responsible for this differentiation; these peaks were 359 
tentatively assigned to different biomolecules which can potentially serve as biomarkers 46, 47. 360 
After the six peaks were identified from the loadings plot, they were then extracted from 361 
polynomial corrected, vector normalised spectra in order to avoid the spectral transformation 362 
that first order differentiation can cause. Classification of the different comparison groups was 363 
conducted using support vector machine (SVM) which is a machine-learning technique to 364 
classify spectral data. For SVM implementation, the pre-processed dataset (i.e., cut, SG 365 
differentiated, vector normalised) was normalised to the [0, 1] range and then the optimal (C, 366 
γ) combination was found using grid search. Sensitivities and specificities were therefore 367 
calculated for each comparison group 48. In order to overcome the limitation of using a small 368 
cohort in this study, G-score values were also calculated to assess the overall performance of 369 
the classification model 44. The G-score is calculated as the square root of sensitivity times 370 
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specificity. Youden’s index was calculated to assess the classifier’s ability to avoid failure. 371 
This parameter is estimated as sensitivity minus (1 – specificity). 372 
Statistical analysis. The values generated after cross-validated PCA-LDA, were imported 373 
into GraphPad Prism 7 to conduct the statistical analyses and calculate the P-values for each 374 
comparison. Differences between two groups were assessed using a Student’s t-test (two-tailed, 375 
non-parametric, Mann-Whitney test, 95% confidence interval). The data were expressed as the 376 
mean ± standard deviation (SD). A P-value of 0.05 or less was considered significant in all 377 
statistical tests. 378 
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Legends for the figures  576 
 577 
 578 
Figure 1. Early stage Alzheimer’s disease (AD) versus healthy individuals. One-579 
dimensional (1D) scores plot after cross-validated PCA-LDA (P < 0.0001, 95% CI = 0.0503 to 580 
0.0622) (A); loadings plot showing the top six discriminatory peaks between the two classes 581 
(B); important peaks along with their tentative assignments 45,46 (C). Data are expressed as the 582 
mean ± standard deviation (SD). A P-value of 0.05 or less was considered significant; P < 0.05 583 
(*) or P < 0.005 (**) or P < 0.0005 (***). 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 594 
 595 
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 596 
Figure 2. Late stage Alzheimer’s disease (AD) versus healthy individuals. One-dimensional 597 
(1D) scores plot after cross-validated PCA-LDA (P <0.0001, 95% CI = 0.0655 to 0.0834) (A); 598 
loadings plot showing the top six discriminatory peaks between the two classes (B); important 599 
peaks along with their tentative assignments 45,46 (C). Data are expressed as the mean ± standard 600 
deviation (SD). A P-value of 0.05 or less was considered significant; P <0.05 (*) or P <0.005 601 
(**) or P <0.0005 (***). 602 
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 605 
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 610 
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 616 
Figure 3. Dementia with Lewy bodies (DLB) versus healthy individuals. One-dimensional 617 
(1D) scores plot after cross-validated PCA-LDA (P <0.0001, 95% CI = 0.0982 to 0.1166) (A); 618 
loadings plot showing the top six discriminatory peaks (B); important peaks along with their 619 
tentative assignments 45,46 (C). Data are expressed as the mean ± standard deviation (SD). A P-620 
value of 0.05 or less was considered significant; P <0.05 (*) or P <0.005 (**) or P <0.0005 621 
(***). 622 
 623 
 624 
 625 
 626 
 627 
 628 
 629 
 630 
 631 
 632 
 633 
 634 
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 635 
Figure 4. Early stage Alzheimer’s disease (AD) versus dementia with Lewy bodies (DLB). 636 
One-dimensional (1D) scores plot after cross-validated PCA-LDA (P <0.0001, 95% CI = -637 
0.0791 to -0.0649) (A); loadings plot showing the top six discriminatory peaks (early AD was 638 
used as reference class) between the two classes (B); important peaks along with their tentative 639 
assignments 45,46 (C). Data are expressed as the mean ± standard deviation (SD). A P-value of 640 
0.05 or less was considered significant; P <0.05 (*) or P <0.005 (**) or P <0.0005 (***). 641 
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 654 
Figure 5. Late stage Alzheimer’s disease (AD) versus dementia with Lewy bodies (DLB). 655 
One-dimensional (1D) scores plot after cross-validated PCA-LDA (P <0.0001, 95% CI = 0.138 656 
to 0.1596) (A); loadings plot showing the top six discriminatory peaks (late AD was used as 657 
reference class) (B); important peaks along with their tentative assignments 45,46 (C). Data are 658 
expressed as the mean ± standard deviation (SD). A P-value of 0.05 or less was considered 659 
significant; P <0.05 (*) or P <0.005 (**) or P <0.0005 (***). 660 
 661 
 662 
 663 
 664 
 665 
 666 
 667 
 668 
 669 
 670 
 671 
 672 
26 
 
 673 
Figure 6. Early stage Alzheimer’s disease (AD) versus late AD. One-dimensional (1D) 674 
scores plot after cross-validated PCA-LDA (P <0.0001, 95% CI = -0.0943 to -0.0624) (A); 675 
loadings plot showing the top six discriminatory peaks (early AD was used as reference class) 676 
(B); important peaks along with their tentative assignments 45,46. (C). Data are expressed as the 677 
mean ± standard deviation (SD). A P-value of 0.05 or less was considered significant; P <0.05 678 
(*) or P <0.005 (**) or P <0.0005 (***). 679 
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Table 1. Patient characteristics.  699 
 
Early stage 
AD 
Late stage  
AD 
DLB Healthya 
Sample size, n 11 15 15 15 
Age, years, mean 
(SD, range) 
62 (10, 50-74) 64 (8, 50-79) 71 (6, 61-80) 54 (18, 23-73) 
APOE4 carriers, n (%) 6 (55) 11 (73) 6 (40) 6 (40)  
Female, n (%) 5 (45) 3 (20) 3 (20) 9 (60) 
Duration, years, mean  
(± SD) 
1.28 (±0.5) 4.56 (±3) 2.46 (±1) n/a 
 700 
AD: Alzheimer’s disease DLB: dementia with Lewy bodies; APOE4: apolipoprotein E4; n/a: not 701 
applicable 702 
a Two individuals from the ‘Healthy’ group had no information on APOE4 load (13%) and gender 703 
(13%). 704 
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Table 2. Sensitivity, specificity and G-score and Youden’s index for the different comparison 721 
groups after classification with support vector machine (SVM).  722 
Comparison Group 
Sensitivity 
(%) 
Specificity 
(%) 
G-Score 
(%) 
Youden’s 
index 
(%) 
Early AD vs 
Healthy 
84 86 85 70 
Late AD vs Healthy 84 77 80 61 
DLB vs Healthy 83 87 85 70 
Early AD vs DLB 81 88 84 69 
Late AD vs DLB 90 93 91 84 
Early AD vs Late 
AD 
66 83 74 49 
AD: Alzheimer’s disease; DLB: dementia with Lewy bodies 723 
